iSERA Lifesciences
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
iSERA Lifesciences allotted 1,61,82,800 fully paid-up equity shares at Rs48.20 per share on a preferential basis through a one-for-one share swap with the shareholders of iSERA Biological. The allotment to 196 investors followed shareholder approval by postal ballot on 21 May 2026 and in-principle approval from BSE on 18 September 2026, and took paid-up capital from 84,08,972 shares to 2,45,91,772 shares. iSERA Biological was an unlisted Pune-based pharmaceutical, biological and biotechnology manufacturing, trading and genomics research business incorporated in July 2016. The target reported turnover of Rs18.36 crore and EBITDA of Rs7.67 crore for FY25. The listed company reported operating revenue of about Rs1.36 crore for FY26 from standalone software development and IT solutions, with no plant, property or intangibles on its books.
Powered by Tijori
iSERA Lifesciences allotted 1,61,82,800 fully paid-up equity shares at Rs48.20 per share on a preferential basis through a one-for-one share swap with the shareholders of iSERA Biological. The allotment to 196 investors followed shareholder approval by postal ballot on 21 May 2026 and in-principle approval from BSE on 18 September 2026, and took paid-up capital from 84,08,972 shares to 2,45,91,772 shares. iSERA Biological was an unlisted Pune-based pharmaceutical, biological and biotechnology manufacturing, trading and genomics research business incorporated in July 2016. The target reported turnover of Rs18.36 crore and EBITDA of Rs7.67 crore for FY25. The listed company reported operating revenue of about Rs1.36 crore for FY26 from standalone software development and IT solutions, with no plant, property or intangibles on its books.
Powered by Tijori
Feb 23 (Reuters) - Covidh Technologies Ltd COVI.BO:
EXECUTES NON-BINDING LOI FOR 100% STAKE OF ISERA BIOLOGICAL
Source text: ID:nBSEbNhr1P
Further company coverage: COVI.BO
(([email protected];;))
Feb 23 (Reuters) - Covidh Technologies Ltd COVI.BO:
EXECUTES NON-BINDING LOI FOR 100% STAKE OF ISERA BIOLOGICAL
Source text: ID:nBSEbNhr1P
Further company coverage: COVI.BO
(([email protected];;))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does iSERA Lifesciences do?
Aptus Industries Limited, a Public Limited Company established in 1993, operates in agricultural software, construction, and infrastructure projects. Headquartered in Hyderabad, Andhra Pradesh.
Who are the competitors of iSERA Lifesciences?
iSERA Lifesciences major competitors are Ace Software Exports, Digispice Tech., Sattrix Info. Sec., Tracxn Technologies, Novus Loyalty, ABM Knowledgeware, Inspirisys Solutions. Market Cap of iSERA Lifesciences is ₹354 Crs. While the median market cap of its peers are ₹342 Crs.
Is iSERA Lifesciences financially stable compared to its competitors?
iSERA Lifesciences seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does iSERA Lifesciences pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. iSERA Lifesciences latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has iSERA Lifesciences allocated its funds?
Companies resources are allocated to majorly unproductive assets like Short Term Loans & Advances
How strong is iSERA Lifesciences balance sheet?
Balance sheet of iSERA Lifesciences is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of iSERA Lifesciences improving?
Yes, profit is increasing. The profit of iSERA Lifesciences is ₹0.14 Crs for Mar 2025, -₹0.1 Crs for Mar 2024 and -₹0.11 Crs for Mar 2023
Is the debt of iSERA Lifesciences increasing or decreasing?
Yes, The net debt of iSERA Lifesciences is increasing. Latest net debt of iSERA Lifesciences is ₹1.56 Crs as of Mar-25. This is greater than Mar-24 when it was ₹0.18 Crs.
Is iSERA Lifesciences stock expensive?
iSERA Lifesciences is not expensive. Latest PE of iSERA Lifesciences is 0, while 3 year average PE is 63.92. Also latest EV/EBITDA of iSERA Lifesciences is 0.0 while 3yr average is 35.11.
Has the share price of iSERA Lifesciences grown faster than its competition?
iSERA Lifesciences has given better returns compared to its competitors. iSERA Lifesciences has grown at ~4179.66% over the last 2yrs while peers have grown at a median rate of -25.0%
Is the promoter bullish about iSERA Lifesciences?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in iSERA Lifesciences is 58.63% and last quarter promoter holding is 58.63%.
Are mutual funds buying/selling iSERA Lifesciences?
There is Insufficient data to gauge this.